Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1. | Zendy

Curtis Cooper | Zendy; Susanggie | Zendy; Michael S. Saag | Zendy; Jenny C. Yang | Zendy; Luisa M. Stamm | Zendy; Hadas DvorySobol | Zendy; Lingling Han | Zendy; Phillip S. Pang | Zendy; John G. McHutchison | Zendy; Douglas T. Dieterich | Zendy; Mark Sulkowski | Zendy

Open Access

Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.

Author(s) -

Curtis Cooper,

Susanggie,

Michael S. Saag,

Jenny C. Yang,

Luisa M. Stamm,

Hadas DvorySobol,

Lingling Han,

Phillip S. Pang,

John G. McHutchison,

Douglas T. Dieterich,

Mark Sulkowski

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw349

Subject(s) - medicine , ledipasvir , sofosbuvir , ribavirin , hepatitis c virus , hepatitis c , clinical trial , human immunodeficiency virus (hiv) , virology , gastroenterology , virus

We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research